Expertise in
8
conditions

Soo Aleman

Karolinska Institutet
Huddinge, AB, SE 
Expertise in
8
conditions
Karolinska Institutet
Huddinge, AB, SE 

Overview

Soo Aleman practices practicing medicine in Huddinge, Sweden.

Ms. Aleman is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Hepatitis D, Hepatitis, Hepatitis C, and Hepatitis B.

She is actively involved in clinical research, co-authoring 145 peer reviewed articles and participating in 1 clinical trial.

Gender

Female

Locations

Karolinska Institutet
Huddinge, AB, Sweden
Other Locations
Stockholm, AB, Sweden
Solna, AB, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3

145 Total Publications

Corrigendum to 'Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort' [JHEP Reports (2026) 19;8(8):101898].
Corrigendum to 'Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort' [JHEP Reports (2026) 19;8(8):101898].
Journal: JHEP reports : innovation in hepatology
Published: September 03, 2026

Frequently Asked Questions about Soo Aleman

Is Soo Aleman a top-rated expert for Hepatitis D?

MediFind is an objective health platform that identifies experts based on real-world data. Soo Aleman is classified as an Elite expert for Hepatitis D, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Soo Aleman participate in research or clinical trials?

Yes. Soo Aleman has published 145 articles and abstracts on conditions like Hepatitis D. You can view a list of Soo Aleman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Aleman's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile